WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Stock Ownership - Who owns Ultragenyx Pharmaceutical?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Ultragenyx Pharmaceutical Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Karah Herdman ParschauerEVP and Chief Legal Officer2026-03-103,508$22.67
$79.53kSell
Karah Herdman ParschauerEVP and Chief Legal Officer2026-03-066,018$21.40
$128.79kSell
Howard HornChief Financial Officer2026-03-031,635$22.40
$36.62kSell
Erik HarrisEVP Chief Commercial Officer2026-03-0210,539$22.80
$240.29kSell
John Richard PinionEVP Chief Quality Operations Officer2026-03-0210,029$22.80
$228.66kSell
Howard HornChief Financial Officer2026-03-025,290$22.80
$120.61kSell
Howard HornChief Financial Officer2026-03-023,119$22.54
$70.30kSell
Dennis Karl HuangEVP Chief Technical Operations Officer2026-03-02999$23.39
$23.37kSell
Theodore Alan HuizengaSVP Chief Accounting Officer2026-03-02148$23.39
$3.46kSell
Theodore Alan HuizengaSVP Chief Accounting Officer2026-03-021,632$22.80
$37.21kSell

1 of 3

RARE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RARE insiders and whales buy or sell their stock.

RARE Shareholders

What type of owners hold Ultragenyx Pharmaceutical Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vanguard Group Inc10.62%10,263,815$223.96MInstitution
Emil D. Kakkis7.56%7,305,949$159.42MInsider
Blackrock Inc6.86%6,631,554$144.70MInstitution
Fmr LLC4.88%4,718,234$102.95MInsider
State Street Corp4.45%4,303,046$93.89MInstitution
Jpmorgan Chase Co4.11%3,974,030$86.71MInstitution
Sands Capital Management LLC3.61%3,485,724$76.06MInstitution
Rtw Investments LP3.10%3,000,139$65.46MInstitution
Baker Bros Advisors LP2.87%2,772,692$60.50MInstitution
Fmr LLC2.76%2,666,249$58.18MInstitution

1 of 3

RARE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RARE85.42%14.58%Net SellingNet Selling
SNDX91.46%8.54%Net SellingNet Selling
ZLAB2.62%1.77%Net BuyingNet Buying
ADPT62.97%37.03%Net SellingNet Selling
MLYS67.62%32.38%Net BuyingNet Selling
View Top Biotech Stocks

Ultragenyx Pharmaceutical Stock Ownership FAQ

Who owns Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ: RARE) is owned by 97.22% institutional shareholders, 16.59% Ultragenyx Pharmaceutical insiders, and 0.00% retail investors. Emil D. Kakkis is the largest individual Ultragenyx Pharmaceutical shareholder, owning 7.31M shares representing 7.56% of the company. Emil D. Kakkis's Ultragenyx Pharmaceutical shares are currently valued at $157.81M.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.